Mogam Biotechnology Research Institute

Other

Neurotech Pharmaceuticals Co., Ltd.

Doo-Hong Park

Soo-Il Chung

Yeup Yoon

Jae-Seung Yoon

Byoung S Kwon

Byung Soo Youn

Soo-il Chung

Seung Jae Baek

Ju-Hyung Ahn

Jung-Seob Kim

Jin-Hyung Ahn

Eun-Kyung Jung

Kong-Ju Lee

Eun-Kyoung Lee

Ho-Jeong Lee

Hyun-Kyung Yu

Jang-Seong Kim

Kwang-Hee Baek

Sun-Mo Oh

Jong-Mook Kim

Seong-Tae Yun

Hyunkyung Yu

Eui-Cheol Jo

The present invention relates to an expression vector for animal cells. Specifically, the present invention relates to an expression vector, pMS vector, pSG vector and pMSG vector, including the human &#x3b2;-globin 5' MAR complementary sequence or/and the transcription termination site of the gastrin gene. An expression system using an expression vector of the present invention can successfully produce recombinant proteins in various animals cells and recombinant protein having a unique structure and function.

Expression vector for animal cell

The present application discloses a method of reducing tumor growth that includes contacting the tumor with a tumor growth reducing effective amount of a composition comprising LK8 or LK68 protein or a functionally equivalent amino acid variant thereof and a pharmaceutically acceptable carrier thereof to a subject having tumor.

Anticancer agent

The present invention relates to a variant of Lkn-1(shLkn-1) with enhanced biological activity, which is a truncated form of Lkn-1, a process for preparing a recombinant shLkn-1 by employing expression vector therefor and pharmaceutical application of the said protein. shLkn-1 is generated by missing 26 amino acid residues from the amino terminus of Lkn-1 to contain 66 amino acids. Recombinant shLkn-1 inhibits colony formation and cell proliferation in vivo, which suggests that it can be used as a potential drug for the antibody production, the treatment during HIV-1 infection, the protection of bone marrow stem cells during chemotherapy or radiotherapy, and the inhibition of leukemia.

Variant of C6 &bgr;-chemokine leukotactin-1(shLkn-1) with enhanced biological activity

The present invention relates to a recombinant expression vector which is prepared by inserting a human parathyroid hormone gene containing a urokinase-specific cleavage site into an L-arabinose inducible vector containing a phosphoribulokinase gene fragment of or its mutated gene as a fusion partner, or its mutate gene as a fusion partner, a recombinant microorganism transformed with the said expression vector, and a process for preparing human parathyroid hormone on a large scale by cultivating the said microorganism in a medium containing L-arabinose. In accordance with the invention, a recombinant human PTH having the same activity of the native human PTH can be prepared in a high yield through the precise control of induction by a manufacturing process which comprises a step of inducing expression of fusion protein in the microorganism transformed with the recombinant expression vector by L-arabinose.

Recombinant expression vector of human parathyroid hormone

Growing community of inventors

Seoul, South Korea

Doo-Hong Park